Free Trial

Orchestra BioMed (OBIO) Competitors

Orchestra BioMed logo
$2.85 -0.01 (-0.35%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$3.24 +0.40 (+13.86%)
As of 04/17/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OBIO vs. TMCI, DCTH, NPCE, SMLR, CLPT, TCMD, NNOX, SMTI, SNWV, and ZIMV

Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Treace Medical Concepts (TMCI), Delcath Systems (DCTH), NeuroPace (NPCE), Semler Scientific (SMLR), ClearPoint Neuro (CLPT), Tactile Systems Technology (TCMD), Nano-X Imaging (NNOX), Sanara MedTech (SMTI), SANUWAVE Health (SNWV), and ZimVie (ZIMV). These companies are all part of the "medical equipment" industry.

Orchestra BioMed vs.

Orchestra BioMed (NASDAQ:OBIO) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.

In the previous week, Treace Medical Concepts had 27 more articles in the media than Orchestra BioMed. MarketBeat recorded 27 mentions for Treace Medical Concepts and 0 mentions for Orchestra BioMed. Treace Medical Concepts' average media sentiment score of 0.13 beat Orchestra BioMed's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company Overall Sentiment
Orchestra BioMed Neutral
Treace Medical Concepts Neutral

Orchestra BioMed currently has a consensus price target of $15.00, indicating a potential upside of 426.32%. Treace Medical Concepts has a consensus price target of $9.93, indicating a potential upside of 54.05%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, research analysts plainly believe Orchestra BioMed is more favorable than Treace Medical Concepts.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orchestra BioMed
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Treace Medical Concepts
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.29

Orchestra BioMed has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orchestra BioMed$2.64M41.39-$49.12M-$1.67-1.71
Treace Medical Concepts$209.36M1.94-$49.53M-$0.90-7.16

Treace Medical Concepts received 9 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 44.83% of users gave Treace Medical Concepts an outperform vote.

CompanyUnderperformOutperform
Orchestra BioMedOutperform Votes
17
100.00%
Underperform Votes
No Votes
Treace Medical ConceptsOutperform Votes
26
44.83%
Underperform Votes
32
55.17%

Orchestra BioMed has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

53.5% of Orchestra BioMed shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 6.7% of Orchestra BioMed shares are held by insiders. Comparatively, 24.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Treace Medical Concepts has a net margin of -30.33% compared to Orchestra BioMed's net margin of -2,179.33%. Treace Medical Concepts' return on equity of -51.12% beat Orchestra BioMed's return on equity.

Company Net Margins Return on Equity Return on Assets
Orchestra BioMed-2,179.33% -107.04% -70.88%
Treace Medical Concepts -30.33%-51.12%-26.36%

Summary

Treace Medical Concepts beats Orchestra BioMed on 11 of the 19 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBIO vs. The Competition

MetricOrchestra BioMedSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$109.19M$4.04B$5.30B$7.35B
Dividend YieldN/A39.51%5.12%4.30%
P/E Ratio-1.7727.6821.8017.80
Price / Sales41.3947.06379.9697.74
Price / CashN/A51.0838.2634.64
Price / Book1.505.816.443.98
Net Income-$49.12M$67.09M$3.21B$247.73M
7 Day Performance-4.36%1.97%2.87%1.81%
1 Month Performance-29.63%-4.84%-8.63%-6.98%
1 Year Performance-39.49%14.47%11.46%1.37%

Orchestra BioMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBIO
Orchestra BioMed
1.192 of 5 stars
$2.85
-0.3%
$15.00
+426.3%
-38.3%$109.19M$2.64M-1.774Gap Down
TMCI
Treace Medical Concepts
2.8456 of 5 stars
$6.76
+0.3%
$9.93
+46.9%
-43.5%$423.56M$209.36M-6.83250News Coverage
Gap Up
DCTH
Delcath Systems
2.9588 of 5 stars
$11.59
+8.7%
$22.75
+96.3%
+159.9%$387.49M$37.21M-8.5960Positive News
Gap Up
NPCE
NeuroPace
2.8442 of 5 stars
$10.67
+2.4%
$15.20
+42.5%
-21.5%$339.28M$79.91M-10.67170Short Interest ↑
Gap Down
SMLR
Semler Scientific
2.3739 of 5 stars
$34.26
+1.5%
$71.00
+107.2%
+26.6%$328.79M$56.29M6.98120Short Interest ↑
CLPT
ClearPoint Neuro
1.575 of 5 stars
$11.54
+0.6%
$25.00
+116.6%
+121.3%$318.87M$31.39M-16.72110News Coverage
Gap Down
TCMD
Tactile Systems Technology
3.2503 of 5 stars
$13.40
+1.0%
$18.00
+34.3%
-5.9%$317.12M$292.98M19.14980Positive News
NNOX
Nano-X Imaging
1.7902 of 5 stars
$4.74
+2.8%
$12.00
+153.2%
-44.4%$273.87M$11.28M-5.58190Analyst Forecast
News Coverage
Gap Up
SMTI
Sanara MedTech
1.7079 of 5 stars
$29.96
+3.1%
$48.50
+61.9%
-6.9%$266.70M$86.67M-30.2660
SNWV
SANUWAVE Health
N/A$30.46
+1.8%
N/AN/A$260.40M$32.63M-7.8140High Trading Volume
ZIMV
ZimVie
2.5928 of 5 stars
$9.44
+3.2%
$19.50
+106.6%
-38.7%$254.80M$449.75M-0.722,700

Related Companies and Tools


This page (NASDAQ:OBIO) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners